Primo Lara, MD, on RCC: Expert Perspective on Three Key Papers
2017 ASCO Annual MeetingPrimo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembrolizumab, atezolizumab, bevacizumab, sunitinib, or pazopanib. (Abstracts 4505, 4507, 4515)
Related Videos
John Marshall, MD, and John Neil Primrose, PhD, MBBS, on Biliary Tract Cancer: Results From the BILCAP Trial
John Marshall, MD, of Georgetown University, and John Neil Primrose, PhD, MBBS, of the University of Southampton, discuss the potentially practice-changing finding...
David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045
David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizuma...
Gary Rodin, MD, on Advanced Cancer: The CALM Psychological Intervention
Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)
Todd M. Gibson, PhD, on Childhood Cancer Survivors: Chronic Disease Trends
Todd M. Gibson, PhD, of St. Jude Children’s Research Hospital, discusses results from the Childhood Cancer Survivor Study, which showed a reduction in serious chronic morbidity mea...
Daniel A. Goldstein, MD, on Pembrolizumab for Lung Cancer: Saving Costs by Adjusting Dosage
Daniel A. Goldstein, MD, of Emory University and Rabin Medical Center, discusses his study findings that show nearly $1 billion in savings when patients receive personal weight-bas...
